(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2011 (17.11.2011)

PCT

(10) International Publication Number
WO 2011/141488 A3

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/485* (2006.01)

(21) International Application Number:
PCT/EP2011/057566

(22) International Filing Date:
10 May 2011 (10.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10162428.6 10 May 2010 (10.05.2010) EP

(71) Applicant *(for all designated States except US)*: **EUROCELTIQUE S.A.** [LU/LU]; 2, avenue Charles de Gaulle, L-1653 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DANAGHER, Helen, Kathleen** [GB/GB]; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0GW (GB). **MOHAMMAD, Hassan** [GB/GB]; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0GW (GB). **WALDEN, Malcolm** [GB/GB]; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0GW (GB). **HAYES, Geoffrey, Gerard** [GB/GB]; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0GW (GB). **WHITEHOUSE, Jonathon Oliver** [GB/GB]; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0GW (GB). **KRISHNAMURTHY, Thinnayam Naganathan** [CA/CA]; 168 Bonis Avenue, Apartment #711, Scarborough, Ontario M1T 3V6 (CA). **VARGAS RINCON, Ricardo Alberto** [CA/CA]; 6602 Harmony Hill, Mississauga, Ontario L5W 1S4 (CA).

(74) Agent: **MAIWALD PATENTANWALTS GMBH**; Dirk BÜHLER, Elisenhof, Elisenstr. 3, 80335 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
5 April 2012

WO 2011/141488 A3

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE

(57) Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone and naloxone, or salts thereof, the manufacture thereof as well as their use for administration to human beings.